GLAND PHARMA
Back to Balance Sheet
|
GLAND PHARMA Last 5 Year Total Current Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Current Liabilities | ₹1,565 Cr | ₹1,398 Cr | ₹729 Cr | ₹582 Cr | ₹513 Cr |
What is the latest Total Current Liabilities ratio of GLAND PHARMA ?
| Year | Total Current Liabilities |
|---|---|
| Mar2025 | ₹1,565 Cr |
| Mar2024 | ₹1,398 Cr |
| Mar2023 | ₹729 Cr |
| Mar2022 | ₹582 Cr |
| Mar2021 | ₹513 Cr |
How is Total Current Liabilities of GLAND PHARMA Trending?
| Years | Total Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹1,565 Cr | 11.91 | |
| Mar2024 | ₹1,398 Cr | 91.78 | |
| Mar2023 | ₹729 Cr | 25.28 | |
| Mar2022 | ₹582 Cr | 13.56 | |
| Mar2021 | ₹513 Cr | - | |
Compare Total Current Liabilities of peers of GLAND PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLAND PHARMA | ₹31,066.4 Cr | -0.5% | 11% | 21.8% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹408,991.0 Cr | 0.1% | -3.2% | -2.6% | Stock Analytics | |
| DIVIS LABORATORIES | ₹162,371.0 Cr | -1.5% | -7.3% | 2.3% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹135,229.0 Cr | -1.3% | -0.7% | 24.4% | Stock Analytics | |
| CIPLA | ₹108,441.0 Cr | 1.5% | -8.1% | -6.3% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹106,407.0 Cr | 3.2% | 5.6% | 3.1% | Stock Analytics | |
GLAND PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLAND PHARMA | -0.5% |
11% |
21.8% |
| SENSEX | 2.9% |
-1.1% |
8.5% |
You may also like the below Video Courses